Serine proteases profiles of Leishmania (Viannia) braziliensis clinical isolates with distinct susceptibilities to antimony.

ABSTRACT: Glucantime (Sb^V) is the first-line treatment against American Tegumentary Leishmaniasis. Resistance cases to this drug have been reported and related to host characteristics and parasite phenotypes. In this study, 12 Leishmania (Viannia) braziliensis isolates from patients that presented clinical cure (Responders-R) and relapse or therapeutic failure (Non-responders-NR) after treatment with antimony, were analyzed. These parasites were assessed by in vitro susceptibility to Sb^III and Sb^V, serine proteases activity measured with substrate (z-FR-AMC) and specific inhibitors (TLCK, AEBSF and PMSF). In vitro susceptibility of axenic amastigotes to Sb^III showed a significant difference between R and NR groups. The protease assays showed that TLCK inhi

SUBMITTER: Zabala-Penafiel A 

PROVIDER: S-EPMC8271011 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature